Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
Science 37 has significantly enhanced patient recruitment and enrollment in over 20 clinical trials that were underperforming. Their proprietary Virtual Site and Patient Recruitment solutions facilitated the identification, recruitment, medical qualification, and enrollment of patients without geographic limitations. This intervention has been effective in Phase 2 through Phase 4 and Observational trials across various therapeutic areas, including Hematology, Hepatology, Infectious Diseases, CNS, Oncology, and Rare Diseases. The company's Patient Recruitment service is available both independently and in combination with their Virtual Site, Metasite™, to accelerate patient access and improve trial outcomes.
- Enhanced recruitment in over 20 underperforming clinical trials.
- Effective in Phase 2 through Phase 4 and Observational trials across multiple therapeutic areas.
- Proprietary solutions facilitated patient identification and enrollment without geographic restrictions.
- Enrollment delays can be costly and create immense pressure to deliver results.
Science 37's recent success in boosting patient recruitment and enrollment for under-performing clinical trials is noteworthy within the medical research community. Enrollment delays are a common bottleneck in clinical research, often leading to increased costs and extended timelines. By using their proprietary Virtual Site and Patient Recruitment solutions, Science 37 is able to break free from traditional geographic limitations, a significant innovation in clinical trial operations.
For retail investors, this development suggests that Science 37 has a competitive edge in the clinical trial marketplace, potentially increasing its market share. This could lead to a more stable revenue stream as more pharmaceutical companies and contract research organizations (CROs) might rely on their services to mitigate enrollment risks. However, the long-term impact will depend on consistent performance and the ability to replicate these results across various therapeutic areas.
From a financial perspective, successfully addressing under-enrollment in clinical trials can translate directly into
However, potential investors should remain cautious. While the short-term benefits are apparent, long-term financial stability will depend on maintaining its technological lead and ensuring that these enrollment solutions remain effective across a broad range of trials and therapeutic areas. Investors should monitor upcoming financial reports for sustained performance and new client acquisitions to validate this growth trajectory.
For market research analysts, Science 37's success story here is an indicator of shifting trends in the clinical trials industry. The move towards virtual and decentralized trials is gaining momentum, driven partly by the need for greater patient diversity and the ability to reach historically underrepresented populations. Science 37's ability to enroll patients without geographic limitations represents a significant advancement in this direction.
Retail investors can view this as a strategic positioning within an evolving market. As the industry continues to prioritize patient accessibility and reduce enrollment barriers, companies that provide innovative solutions like Science 37 are likely to see increased demand. Long-term success will depend on their ability to adapt and integrate further technological advancements, ensuring they stay ahead of competitors.
Nearly 20 studies have successfully leveraged Science 37's medical and operational expertise to boost patient recruitment and enrollment activities
RESEARCH TRIANGLE PARK, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets. Leveraging its proprietary Virtual Site and Patient Recruitment solutions, Science 37 efficiently identified, recruited, medically qualified, and enrolled patients without geographic restrictions.
"Enrollment delays can be costly and create immense pressure to deliver results,” commented Brian Smith, Senior VP of Project Delivery at Science 37. “Traditionally, study teams address this by starting up more sites and/or adding patient recruitment. However, today's study teams need solutions that expand patient access to their study regardless of their location. Science 37 provides access to patient populations that no traditional site can match."
Science 37 has successfully supplemented enrollment in a variety of studies, including Phase 2 through Phase 4 and Observational trials across therapeutic areas such as Hematology, Hepatology, Infectious Diseases, CNS, Oncology, and Rare Diseases like Primary Sclerosing Cholangitis and Fragile X Syndrome.
Science 37’s Patient Recruitment is available on a standalone basis to clinical research sponsors and CROs looking to enhance their patient enrollment efforts, or in combination with Science 37’s industry-leading flagship Virtual Site, the Metasite™, as part of an accelerated patient access offering. For more information, please visit www.science37.com.
About Science 37
Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Metasite™ and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration. To learn more, visit www.science37.com, or email science37@science37.com.
To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.
Media Inquiries
Science 37
PR@science37.com
FAQ
What impact has Science 37 had on under-enrolling clinical trials?
How does Science 37's Virtual Site solution benefit clinical trials?
What types of clinical trials has Science 37 been involved in?
Is Science 37's Patient Recruitment available independently?
What are the key features of Science 37's recruitment solutions?
